(Q35911827)

11 August 2017

1 reference

title

Safety of a new oral contraceptive containing drospirenone (English)

1 reference

11 August 2017

Lothar A J Heinemann

1

1 reference

11 August 2017

Jürgen Dinger

series ordinal

2

1 reference

11 August 2017

publication date

1 January 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

27

1 reference

11 August 2017

issue

13

1 reference

11 August 2017

page(s)

1001-1018

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200427130-00003

11 August 2017

exact match

0 references

cites work

Myocardial infarction and third generation oral contraceptives: aggregation of recent studies

1 reference

12 December 2020

The changing scene--an unnecessary pill crisis

1 reference

12 December 2020

Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis

1 reference

12 December 2020

Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens

1 reference

12 December 2020

Population-based study of risk of venous thromboembolism associated with various oral contraceptives

1 reference

12 December 2020

Recent oral contraceptive use patterns in four European countries: evidence for selective prescribing of oral contraceptives containing third-generation progestogens.

1 reference

12 December 2020

Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception

1 reference

12 December 2020

Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women

1 reference

12 December 2020

Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone

1 reference

12 December 2020

Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation

1 reference

12 December 2020

Selective prescribing of third generation oral contraceptives (OCs)

1 reference

12 December 2020

Case-control studies on venous thromboembolism: bias due to design? A methodological study on venous thromboembolism and steroid hormone use.

1 reference

12 December 2020

Recurrent use of newer oral contraceptives and the risk of venous thromboembolism

1 reference

12 December 2020

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

1 reference

12 December 2020

Drospirenone: pharmacology and pharmacokinetics of a unique progestogen

1 reference

12 December 2020

Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties.

1 reference

12 December 2020

Under-reporting of adverse drug reactions in general practice

1 reference

12 December 2020

The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea

1 reference

12 December 2020

Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study.

1 reference

12 December 2020

Venous thrombosis after long-haul flights

1 reference

12 December 2020

Venous thromboembolism and oral contraceptive use: a methodological study of diagnostic suspicion and referral bias.

1 reference

12 December 2020

Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components

1 reference

12 December 2020

The role of selective prescribing in the increased risk of VTE associated with third-generation oral contraceptives

1 reference

12 December 2020

Concordant and discordant effects on cardiovascular risks exerted by oestrogen and progestogen in women using oral contraception and hormone replacement therapy. ESHRE Capri Workshop Group

1 reference

12 December 2020

Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers

1 reference

12 December 2020

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

12 December 2020

The 1995 pill scare revisited: anatomy of a non-epidemic

1 reference

12 December 2020

Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen

1 reference

12 December 2020

Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment

1 reference

12 December 2020

First-time use of newer oral contraceptives and the risk of venous thromboembolism

1 reference

12 December 2020

Comparative pharmacology of newer progestogens

1 reference

12 December 2020

Additive effect of drospirenone/17-beta-estradiol in hypertensive postmenopausal women receiving enalapril

1 reference

12 December 2020

Thrombotic diseases in young women and the influence of oral contraceptives

1 reference

12 December 2020

Final report on the aspirin component of the ongoing Physicians' Health Study

1 reference

12 December 2020

Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events

1 reference

12 December 2020

The differential risk of oral contraceptives: the impact of full exposure history

1 reference

12 December 2020

The Transnational Study on Oral Contraceptives and the Health of Young Women. Methods, results, new analyses and the healthy user effect.

1 reference

12 December 2020

Could preferential prescribing and referral behaviour of physicians explain the elevated thrombosis risk found to be associated with third generation oral contraceptives?

1 reference

12 December 2020

Third generation oral contraceptives and risk of venous thrombosis: meta-analysis

1 reference

12 December 2020

Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study

1 reference

12 December 2020

The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women.

1 reference

12 December 2020

Dutch GPs warned against new contraceptive pill

1 reference

12 December 2020

Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives.

1 reference

12 December 2020

10.2165/00002018-200427130-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

11 August 2017

1051503641

0 references

1 reference